Multimedia Available: FDA Approves Amgen's Neulasta for Serious & Frequent Chemotherapy Side Effect
Amgen (Nasdaq:AMGN) announced that the U.S. Food and Drug
Administration has approved Neulasta(TM) (pegfilgrastim). Neulasta,
administered as a single fixed dose per chemotherapy cycle, for
decreasing the incidence of infection, as manifested by febrile
neutropenia (fever associated with a severe drop in infection-fighting
white blood cells) in patients with non-myeloid malignancies receiving
myelosuppressive anti-cancer drugs.
You can reach the story directly by going to
This multimedia news story is for free and unrestricted use on
your news information site (and for print or broadcast too). Visit
http://www.newstream.com to download video, audio, text, graphics, and
If you have any questions about the story, or about Newstream.com,
please write to us at email@example.com.